沃拉西尼在异柠檬酸脱氢酶突变型胶质瘤治疗中的作用。

IF 16.4 1区 医学 Q1 CLINICAL NEUROLOGY
Macarena I de la Fuente, Mehdi Touat, Martin J van den Bent, Matthias Preusser, Katherine B Peters, Robert J Young, Raymond Y Huang, Benjamin M Ellingson, David Capper, Joanna J Phillips, Lia M Halasz, Helen A Shih, Roberta Rudà, Mary Jane Lim-Fat, Deborah T Blumenthal, Michael Weller, Yoshiki Arakawa, James R Whittle, François Ducray, David A Reardon, Wenya Linda Bi, Giuseppe Minniti, Rifaquat Rahman, Shawn Hervey-Jumper, Susan M Chang, Patrick Y Wen
{"title":"沃拉西尼在异柠檬酸脱氢酶突变型胶质瘤治疗中的作用。","authors":"Macarena I de la Fuente, Mehdi Touat, Martin J van den Bent, Matthias Preusser, Katherine B Peters, Robert J Young, Raymond Y Huang, Benjamin M Ellingson, David Capper, Joanna J Phillips, Lia M Halasz, Helen A Shih, Roberta Rudà, Mary Jane Lim-Fat, Deborah T Blumenthal, Michael Weller, Yoshiki Arakawa, James R Whittle, François Ducray, David A Reardon, Wenya Linda Bi, Giuseppe Minniti, Rifaquat Rahman, Shawn Hervey-Jumper, Susan M Chang, Patrick Y Wen","doi":"10.1093/neuonc/noae259","DOIUrl":null,"url":null,"abstract":"<p><p>Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits and high mortality rates due to tumor progression, coupled with significant morbidity from current treatment modalities. Although surgery, radiation therapy, and chemotherapy improve survival, these treatments can adversely affect cognitive function, quality of life, finances, employment status, and overall independence. Consequently, there is an urgent need for innovative strategies that delay progression and the use of radiation therapy and chemotherapy. The recent Federal Drug Administration (FDA) approval of vorasidenib, a brain-penetrant small molecule targeting mutant IDH1/2 proteins, heralds a shift in the therapeutic landscape for IDH-mutant gliomas. In this review, we address the role of vorasidenib in the treatment of IDH-mutant gliomas, providing a roadmap for its incorporation into daily practice. We discuss ongoing clinical trials with vorasidenib and other IDH inhibitors, as single-agent or in combination with other therapies, as well as current challenges and future directions.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"1135-1148"},"PeriodicalIF":16.4000,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187374/pdf/","citationCount":"0","resultStr":"{\"title\":\"The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.\",\"authors\":\"Macarena I de la Fuente, Mehdi Touat, Martin J van den Bent, Matthias Preusser, Katherine B Peters, Robert J Young, Raymond Y Huang, Benjamin M Ellingson, David Capper, Joanna J Phillips, Lia M Halasz, Helen A Shih, Roberta Rudà, Mary Jane Lim-Fat, Deborah T Blumenthal, Michael Weller, Yoshiki Arakawa, James R Whittle, François Ducray, David A Reardon, Wenya Linda Bi, Giuseppe Minniti, Rifaquat Rahman, Shawn Hervey-Jumper, Susan M Chang, Patrick Y Wen\",\"doi\":\"10.1093/neuonc/noae259\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits and high mortality rates due to tumor progression, coupled with significant morbidity from current treatment modalities. Although surgery, radiation therapy, and chemotherapy improve survival, these treatments can adversely affect cognitive function, quality of life, finances, employment status, and overall independence. Consequently, there is an urgent need for innovative strategies that delay progression and the use of radiation therapy and chemotherapy. The recent Federal Drug Administration (FDA) approval of vorasidenib, a brain-penetrant small molecule targeting mutant IDH1/2 proteins, heralds a shift in the therapeutic landscape for IDH-mutant gliomas. In this review, we address the role of vorasidenib in the treatment of IDH-mutant gliomas, providing a roadmap for its incorporation into daily practice. We discuss ongoing clinical trials with vorasidenib and other IDH inhibitors, as single-agent or in combination with other therapies, as well as current challenges and future directions.</p>\",\"PeriodicalId\":19377,\"journal\":{\"name\":\"Neuro-oncology\",\"volume\":\" \",\"pages\":\"1135-1148\"},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2025-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187374/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/neuonc/noae259\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noae259","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

异柠檬酸脱氢酶(IDH)突变胶质瘤是年轻人中最常见的恶性原发性脑肿瘤。这种情况给患者及其护理人员带来了沉重的负担,其特点是神经认知缺陷和肿瘤进展导致的高死亡率,加上目前治疗方式的显著发病率。虽然手术、放疗和化疗可以提高生存率,但这些治疗会对认知功能、生活质量、经济状况、就业状况和整体独立性产生不利影响。因此,迫切需要创新的策略,以延缓进展和使用放射治疗和化疗。最近美国联邦药物管理局(FDA)批准了vorasidenib,一种靶向突变IDH1/2蛋白的脑渗透小分子,预示着idh突变胶质瘤治疗前景的转变。在这篇综述中,我们讨论了vorasidenib在治疗idh突变胶质瘤中的作用,为其纳入日常实践提供了路线图。我们讨论了vorasidenib和其他IDH抑制剂正在进行的临床试验,作为单药或与其他疗法联合,以及当前的挑战和未来的方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.

Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits and high mortality rates due to tumor progression, coupled with significant morbidity from current treatment modalities. Although surgery, radiation therapy, and chemotherapy improve survival, these treatments can adversely affect cognitive function, quality of life, finances, employment status, and overall independence. Consequently, there is an urgent need for innovative strategies that delay progression and the use of radiation therapy and chemotherapy. The recent Federal Drug Administration (FDA) approval of vorasidenib, a brain-penetrant small molecule targeting mutant IDH1/2 proteins, heralds a shift in the therapeutic landscape for IDH-mutant gliomas. In this review, we address the role of vorasidenib in the treatment of IDH-mutant gliomas, providing a roadmap for its incorporation into daily practice. We discuss ongoing clinical trials with vorasidenib and other IDH inhibitors, as single-agent or in combination with other therapies, as well as current challenges and future directions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neuro-oncology
Neuro-oncology 医学-临床神经学
CiteScore
27.20
自引率
6.30%
发文量
1434
审稿时长
3-8 weeks
期刊介绍: Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field. The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信